Browsing Category News

And The Global Outlook For Drug Spending Is…

To some, a forecast is an opportunity to see the glass as half full. To others, the glass may be half empty. Then again, it is just a stupid glass. Consider the latest projection from IMS Health, which offers some good news and bad news for just about everyone. In its most recent annual briefing, […]

Read More »

Category : News

Media Does Poor Job of Disseminating Info on Pharma, FDA

FDA’s regulations, policies and actions are multi-faceted and complicated. Oftentimes, it is hard to interpret what the agency is doing and why. We all depend on good analysis to understand where the agency has been and where it is headed. Unfortunately, some of what we read about FDA is poorly reasoned or distorted by the […]

Read More »

Category : News

The Merck Hepatitis C Med: Update

Late last week, the FDA approved a much-anticipated hepatitis C treatment from Merck, which the drugmaker inherited as part of its acquisition of Schering-Plough. The move, which is the first FDA endorsement of a new hepatitis C med in a decade, came just 10 days before Vertex Pharmaceuticals is expected to win approval of its […]

Read More »

Category : News

FDA Issues 5 New International Warning Letters

The “Most Recent Warning Letters” section of the FDA website lists five Warning Letters to international firms. The Warning Letters were posted on May 10 and will disappear into the Warning Letter labyrinth on the website in a few days (see previous post). They are to firms in both Europe and Asia and come from […]

Read More »

Category : News

FDA: For Corrective Action Plans, Where are the Resources?

Can you imagine the stream of firms that venture in to their respective FDA district offices to give presentations on their Warning Letter response and to offer their assurance that they truly “get it”? You can be sure that theses firms had several dry runs and dress rehearsals to hone their material before stepping into […]

Read More »

Category : News

Will Pfizer Pay $2B To Settle A Protonix Probe?

Two months ago, Pfizer disclosed that talks are under way with the US Department of Justice to settle charges the drugmaker committed fraud against government health programs by failing to report discounts and rebates for its Protonix heartburn med. And at the time, Pfizer also disclosed the feds alleged its potential liability is more than […]

Read More »

Category : News

FDA’s Warning Letter “Close-Out” Process Is Not Working

In an August 2009 speech to the Food and Drug Law Institute, FDA Commissioner Margaret A. Hamburg, M.D., emphasized the importance of enforcement (see our previous post here). Among other actions announced by Dr. Hamburg was a warning letter “close-out” process. Dr. Hamburg stated that “[i]f the FDA can determine, usually based on a re-inspection, […]

Read More »

Category : News

Genzyme Charged With Double Standard By Patients

In the latest flap over Genzyme, its ongoing manufacturing problems and subsequent product shortages, a group of Fabry patients are charging the biotech has employed a double standard when it comes to providing its Fabrazyme med to US patients and those in Europe. New Webinar – July 28 – Dangerous Documents: How to Avoid Landmines […]

Read More »

Category : News

Biosimilar User Fees-FDA Requests Comments But When FDA Plans to Issue Guidance for Biosimilar Pathway Remains Unclear

On May 10, FDA published a Federal Register Notice requesting comments on FDA’s proposed development of a user fee program for biosimilar and interchangeable biosimilar biological product applications submitted under Section 351(k) of the Public Health Service Act (“PHS Act”). The biosimilar pathway was added to the PHS Act by the Biologics Price Competition and […]

Read More »

Category : News

Drugmakers gear up to copy biotech drugs in U.S.

NEW YORK (Reuters) – Plenty of industry players want a piece of the U.S. market for generic versions of complex biotech drugs, but winners are likely to need the marketing muscle of a big pharmaceutical company. That is a departure from the traditional generic drug industry, which has given rise to dozens of companies that […]

Read More »

Category : News

Subscribe Now

Featured Partner